NCT07293052

Brief Summary

Breast conservation surgery is equivalent to mastectomy for early stage breast cancer patients. Central quadrant tumours can be treated with various oncoplastic techniques with a satisfactory aesthetic outcome and low morbidity. Grisotti flap and reverse mirror grisotti flap are the favourable viable surgical options for central quadrant breast tumours. our hypothesis is that there is a difference in the outcome between Grisotti versus Reverse Mirror Grisotti flap in centrally located breast cancers.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
106

participants targeted

Target at P50-P75 for not_applicable breast-cancer

Timeline
Completed

Started Nov 2025

Shorter than P25 for not_applicable breast-cancer

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 4, 2025

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

November 26, 2025

Completed
22 days until next milestone

First Posted

Study publicly available on registry

December 18, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 4, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 4, 2026

Completed
Last Updated

December 18, 2025

Status Verified

December 1, 2025

Enrollment Period

6 months

First QC Date

November 26, 2025

Last Update Submit

December 15, 2025

Conditions

Keywords

Central Quadrant BreastGrisotti flapReverse Mirror Grisotti Flap

Outcome Measures

Primary Outcomes (1)

  • Flap viability

    Absence of necrosis of new areola formed as seen clinically at 48 hours and 7th day postoperatively. Flap viability categories: A (None): No necrosis. B (Color Change): Color change suggesting impaired perfusion or ischemic injury. C (Partial Thickness): Partial thickness skin flap necrosis resulting in wound breakdown. D (Full Thickness): Full thickness skin flap necrosis.

    7 days

Secondary Outcomes (2)

  • Cosmetic outcome

    7 days

  • Seroma formation

    7 days

Study Arms (2)

Grisotti Flap

EXPERIMENTAL

Grisotti flap will be used in this arm for the oncoplastic breast surgery.

Procedure: Grisotti Flap

Reverse Mirror Grisotti flap

ACTIVE COMPARATOR

Reverse Mirror Grisotti flap will be used in this group for the oncoplastic breast surgery.

Procedure: Reverse Mirror Grisotti Flap

Interventions

Grisotti FlapPROCEDURE

The Grisotti flap is a local rotational flap used to reconstruct defects after removing a central breast cancer, often involving the nipple-areola complex (NAC). It uses tissue from the inferior pole of the breast to fill the central defect. The dermoglandular flap will be raised on infero-lateral perforators of intercostal arteries and will be rotated and advanced to fill the gap .

Grisotti Flap

The reverse-mirror version is a modification where the flap is flipped and reoriented, using the internal mammary vessels as the primary blood supply. The dermoglandular flap will be raised on the medial perforators of internal mammary artery and will be rotated and advanced to fill the defect.

Reverse Mirror Grisotti flap

Eligibility Criteria

Age25 Years - 70 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility DetailsFemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed cases of breast cancer patients
  • Gender: Females
  • Age: 25-70 years
  • T1 (\<2cm) and T2 (2-5cm) tumors with or without prior systemic therapy
  • Tumor located in the NAC or located within 2 cm of the edge of the areola

You may not qualify if:

  • Metastatic breast cancer
  • Inflammatory breast cancer
  • Patients not willing for post-operative radiotherapy
  • High tumour-breast ratio

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

King Edward Medical University

Lahore, Punjab Province, 54000, Pakistan

Location

Related Publications (5)

  • Abdelkader AA, El-Fayoumi T, Roushdy A, Asal MF. Comparison between conventional and oncoplastic breast surgeries regarding resection margins and local recurrences in breast cancer: Retrospective study. The Egyptian Journal of Surgery. 2023; 7;42(4).

    RESULT
  • Ozgul H, Celik O, Sakar B, Celik A, Oener OZ. Postoperative patient satisfaction and oncological Outcomes of Grisotti flap vs. Total mastectomy: A retrospective analysis

    RESULT
  • Koppiker CB, Noor AU, Joshi S, Mishra R, Sivadasan P, Sheikh S., et al.Pushing the Boundaries for Centrally Located Breast Tumors in Oncoplastic Breast Surgery: A Single Centre Audit. medRxiv. 2024 ; 25:2024-11.

    RESULT
  • Siddiqui R, Alsuwaidi SA, Irkorucu O, Mehmood MH, Khan NA. The Increasing Importance of Breast Cancer in the United Arab Emirates. Asia Pac J Clin Oncol. 2025 Nov 15. doi: 10.1111/ajco.70050. Online ahead of print.

  • Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, Jemal A, Siegel RL. Breast cancer statistics 2024. CA Cancer J Clin. 2024 Nov-Dec;74(6):477-495. doi: 10.3322/caac.21863. Epub 2024 Oct 1.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

November 26, 2025

First Posted

December 18, 2025

Study Start

November 4, 2025

Primary Completion

May 4, 2026

Study Completion

May 4, 2026

Last Updated

December 18, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will share

Informed consent will be obtained from all individual participants with diagnosis of central quadrant breast tumors as per operational definition, and data will be collected on predesigned proforma. Information will include name, age, gender, medical registration number, contact and residence.

Shared Documents
STUDY PROTOCOL, SAP, ICF
Time Frame
6 months after publication
Access Criteria
IPD could be provided after contacting with the principal investigator. Other researchers requiring information excluding personal data will be provided only for ethical and educational purposes.

Available IPD Datasets

Study Protocol Access

Locations